HOUSTON--(BUSINESS WIRE)--Sept. 6, 2006--Power3 Medical Products, Inc. (OTCBB: PWRM), said today it has discovered 11 biomarkers which have demonstrated the ability to identify Parkinson's disease in its early stages through serum-based testing, as well as differentiate between Parkinson's and Parkinson's-like diseases. A leading proteomics company, Power3 Medical (www.Power3Medical.com) is developing proteomic testing and biomarker discovery for early detection, monitoring, and staging of a broad range of diseases, including Alzheimer's, Parkinson's, and ALS (Lou Gehrig's disease).
